Try our Advanced Search for more refined results
Life Sciences - November, 2013
240 articles
- AstraZeneca, Ranbaxy Can't Ax Claims In Nexium Antitrust MDL
- Biosig Asks High Court To Skip Patent Indefiniteness Case
- DNA Testing Co. Responds To FDA's Demand, Defends Product
- A Snapshot Of In-House Counsel Compliance In 2014
- Drugmaker Wockhardt Faces Yet Another FDA Import Ban
- Stem Cell Patent Case May Limit Standing For USPTO Appeals
- Abbott Accused Of Overcharging Nonprofit $2M For HIV Meds
- Novartis Says Accord Can't Make, Sell Generic Bone Drug
- USTR Says Stance On Drug Patents 'Flexible' In TPP Talks
- Rite Aid Latest Target Of Glucosamine False Ad Litigation
- Female Powerbrokers Q&A: Sidley's Sara Brody
- Female Powerbrokers Q&A: Morgan Lewis' Grace Speights
- Dechert, Sullivan Steer CVS To $2.1B Infusion Biz Buy
- SillaJen Pays $150M For Tumor Treatment Firm
- High Court Birth Control Case Tests Scope Of Biz Rights
- Narrow Critique Does Not Alter EPA Nano Risk Assessment
- Purdue's Bid To Split OxyContin Patent Suit Gets Rejected
- Dental Implant Co. Sanctioned For Destroying Docs In IP Row
- Policy Groups Warn 9th Circ. Of Drug Cleanup Law
- Bristol-Myers Insured Employees Without Consent, Suit Says
- EMA, Drug Giants Join Push To Reform Vaccine Monitoring
- Myriad Says Invitae Is Infringing Cancer Testing Patents
- Hebei Can't Dodge $153M Penalty In Vitamin C Class Action
- Deals Rumor Mill: Repsol, Blackstone, RBS
- Thermo Fisher Sheds 3 Units, Earns EU Nod On Life Tech Buy
- Novartis Can't Apply NJ Punitives Cap In 3 Zometa Suits
- Travelers Says Claims Not Time-Barred In $47M Pfizer Suit
- Elliott Again Lifts Stake In $8.2B Buyout Target Celesio
- Female Powerbrokers Q&A: Mayer Brown's Libby Raymond
- Female Powerbrokers Q&A: Reed Smith's Colleen Davies
- Supreme Court To Review ACA Contraception Mandate
- Savient's Unsecured Creditors Blast Cash-Collateral Motion
- FDA Scrutiny Looms For Unapproved Research Tests
- Pfizer Escapes FCA Suit Over Anti-Fungal Drug Promotions
- DNA Testers On Notice As FDA Warns Wife Of Google's Brin
- Vitamin Shoppe Sues Seeger Weiss Over Class Action Site
- Defendant In BigLaw Insider Trading Case Mulls Settlement
- FDA Loosens Restrictions On GSK's Avandia
- AIG Must Pay $3.75M To Cover Ad Injury Claims, Jury Says
- Shire Targets Apotex Over Plan For Generic ADHD Drug
- Texas High Court Rejects Medicaid Rate Challenge
- Teva, Mylan Reach Deal Ending MS Drug Litigation In Europe
- Medical Device Co. Says Exec Misappropriated Trade Secrets
- Insurer Disputes Coverage For NECC-Linked Compounder
- Deals Rumor Mill: Blackstone, Glencore, Equity Residential
- Expect More Rulings Invalidating Patents Under Section 101
- Female Powerbrokers Q&A: Hogan Lovells' Janet McDavid
- Female Powerbrokers Q&A: DLA Piper's Lisa Haile
- Cadence Prevails Against Exela In Generic Ofirmev Row
- Ex-Lilly Sales Rep Wants Contract Case In Fla. State Court
- Merck Says Claims Too Varied For Cert. In $100M Bias Suit
- Canada High Court OKs Ban On Pharmacy-Brand Generics
- Judge Backs Jury Finding In J&J Body Powder Cancer Suit
- FDA Calls Out Amgen Over Misleading Anemia Drug Claims
- Shandong Weigao Inks $312M Deal To Sell Biosensors Stake
- Taylor English Lands Bryan Cave Product Liability Pro
- Fed. Circ. Reverses Rejection Of Psoriasis Drug Patent
- Female Powerbrokers Q&A: Norton Rose's Jane Smith
- Female Powerbrokers Q&A: Jones Day's Mary Ellen Powers
- Deals Rumor Mill: Time Warner, BC Partners, Spotify
- J&J Takes Innovative, If Pricey, Route To Ending Hip Suits
- China Must Double-Down On Trade Secret Protection
- In New FCA World, Anyone's A Whistleblower
- Reorganized Rotech Says Baker & McKenzie Lied To Court
- Health Fund Fights Dismissal Of GSK Copay Coupon Suit
- Axinn Veltrop Adds IP Litigator From Curtis Mallet-Prevost
- FDA Rips 'Troubling' Drug Promo In Repeat Warning Letter
- Female Powerbrokers Q&A: Weil's Mindy Spector
- Female Powerbrokers Q&A: Hunton & Williams' Sandy Collins
- Hologic Opts For Poison Pill After Icahn Discloses Stake
- Philips, Zoll Can't Escape Defibrillator Patent Suits
- Doryx Indirect Purchasers Denied Cert. In Warner Antitrust Suit
- Even $2.5B Can't Buy An End To J&J's Hip Troubles
- GNC Hit With Suit Linking Supplement To Hepatitis
- 25 Drug Cos. Put Up $88M To Escape Price-Rigging Suits
- How Some Attorneys Succeed Where The 'Elite' Fail
- In-House Labs Require Health Investor Due Diligence
- FDA Restricts Use Of 2 Astellas Heart Test Drugs
- Spanish Court Finds Grunenthal Liable In Thalidomide Case
- Female Powerbrokers Q&A: Morgan Lewis' Jami McKeon
- Female Powerbrokers Q&A: Sidley's Sara Gourley
- US Pushing Hatch-Waxman Protections In TPP
- Bayer Pay-For-Delay Deal A Taste Of Post-Actavis Climate
- $25M Hydroxycut Settlement Denied In False Ad MDL
- J&J Unit Hit With Suit Over Rheumatoid Arthritis Drug
- 5 Ways To Make The FCA Fairer And More Effective
- Mapping The Divide Over Stream Of Commerce Doctrine
- FTC Eyes Disgorgement In Cephalon Pay-For-Delay Fight
- Horizon Pays $35M For AstraZeneca's Arthritis Drug Rights
- 9th Circ. Upholds Dismissal Of Melatonin Brownie Claims
- DSM Inks $2.6B Spinoff Deal With JLL Partners
- BMS Says Use Of Private Attys In Miss. Plavix Case Is Illegal
- Daiichi Sankyo Escapes Antitrust MDL Over Generic Lipitor
- Female Powerbrokers Q&A: Miller Canfield's Megan Norris
- Expert Deposition Tips For Young Lawyers
- Female Powerbrokers Q&A: Buchanan's Wendy Newton
- J&J To Pay $2.5B To Settle Hip Implant Litigation
- Senate Approves Drug Compounding Reform Bill
- Janssen Owes Family $10M In Topamax Suit, Jury Says
- Bayer's $74M Cipro Pay-For-Delay Deal Approved In Calif.
- 3rd Circ. Affirms Plavix Injury Dismissals in NJ
- J&J Rips Derivative Suit Over Ex-CEO's $30M Salary
- CareFusion Pays GE $500M For Medical Disposables Biz
- NY Doc Says Remington Ripped Off His Hair-Removal Patents
- US Agents Seize $2M In DMAA Supplements
- Supreme Court Roundup: 2012 To The Term Ahead
- 9 Firms Surge Onto GC All-Stars List
- Skadden The Firm Most Loved By General Counsel
- Fed. Circ. Upholds $10M Medtronic Patent Verdict
- 8th Circ. Returns Boston Scientific Mesh Suits To Fed. Court
- Texas, Mich. Zoloft Suits Show No Deception, Pfizer Says
- 9 Top Firms Tumble From List Of GC Favorites
- FDA Asks Texas Compounder To Halt Sterile Drug Production
- FDA Lays Out Drug Naming Standards For Advertisements
- 3 Pharmacists Suspended For Painkiller Distribution Ring
- Economics Of Irreparable Harm In Pharma Patent Litigation
- High Court Accepts Chesley's Resignation From Bar
- GCs Name Most Arrogant Law Firms
- More Firms Get Serious About Keeping GCs Happy
- When It Comes To Law Firms, Size Doesn't Matter, GCs Say
- Female Powerbrokers Q&A: Irell & Manella's Andra Greene
- Female Powerbrokers Q&A: Thompson & Knight's Emily Parker
- Biosimilar-Substitution Restrictions Head To Pa. Senate
- Appeal In Reglan Preemption Row Blasted In Pa. High Court
- FDA Trans Fats Decision Could Affect Other Ingredients
- Fed. Circ. Affirms Invalidity Ruling In Prosthetics IP Dispute
- Female Powerbrokers Q&A: Quarles & Brady's Kim Johnson
- Female Powerbrokers Q&A: Duane Morris' Dominica Anderson
- PE Owners Mull $1.2B Sale Of Medpace Clinical Research Unit
- Obama Names ACA Supporter As Surgeon General
- FDA Calls For Antiseptic Label Changes To Limit Risk
- Takeaways From Stryker's FCPA Settlement
- Nexium Buyers Win Class Cert In AstraZeneca Antitrust MDL
- Doc Block: Ex-SAC Trader Slams Feds In Discovery Row
- Ex-FDA Heads Want FDA To Cut Antibiotic Use In Livestock
- Nelson Mullins Snags Health Care Pros From LeClairRyan
- Novartis Fails To Wipe Out $1.3M Zometa Verdict
- Actavis Testosterone Drug Flouts 6 Patents, Eli Lilly Says
- High Court Snubs Teva Bid To Stay Copaxone Invalidity Ruling
- Elliott Pumps Up Stake In $8.2B Takeover Target Celesio
- Pay-For-Delay Remains Top Priority For Ramirez's FTC
- FDA Floats Plan For Streamlined Device Evaluation
- NJ Men Cop To Insider Trading With Celgene, Stryker Stock
- 1st Biosimilars Act Ruling May Limit Patent Challenges
- Eli Lilly, Others Urge 6th Circ. To Toss Darvocet Appeal
- Ad Watchdog Wrong On Sleep Aid Claims, Review Panel Finds
- Reorganized Rotech Objects To $1M Baker & McKenzie Fees
- Suits Target Endo, Actavis Over Lidoderm Pay-For-Delay
- A Season Of Uncertainty In GMO Labeling
- AmerisourceBergen Beats Online Posters' Bid To Hide IDs
- Counterfeit Male Enhancement Drug Poses Risks, FDA Warns
- J&J To Pay $4B To Settle Hip Implant Suits
- Boehringer Sued Over $120M Pay-For-Delay On Stroke Drug
- J&J Trying To Back Out Of 77 Risperdal Deals, Plaintiffs Say
- FDA Rips Aegerion Exec For Drug Promo Claims On CNBC
- Pressured By Stockholders, Struggling Solta May Seek Sale
- Pfizer Settles Retail Pharmacies' Antitrust Claims
- Epstein Becker Green Snags IP, Life Sciences Pro
- 4 More Reforms That Would Improve FCA
- Deals Rumor Mill: TPG Capital, Adcock, Carlos Slim
- Teva Agrees To Pay $720M In Israeli Tax Agreement
- McNeil Asks Pa. Appeals Court To Boot $10M Motrin Verdict
- There May Be A Paradigm Shift In Generic Drug Labeling
- When Transfer Of Drug Patent Rights Is Reportable To FTC
- FDA Labeling Rule Creates Liability Risk For Generics Cos.
- Magistrate OKs DePuy Trade Secrets Claims Against Reps
- Dr. Oz Can Testify In Medtronic's Heart Valve Patent Suit
- Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.
- Lilly Sues Slew Of Insurers Over Brazil Tort Claims
- Amarin Appeals FDA Ruling On Fish Oil Drug's Expansion
- Law360 MVP Awards Go To Legal Top Guns From 58 Firms
- Deals Rumor Mill: AstraZeneca, ICBC, Johnson & Johnson
- Pfizer, Mylan Settle With Mass. AG Over EpiPen Commercial
- Brown Rudnick Plucks Life Sciences Expert From Bingham
- FDA Rule Would Allow Generics Makers To Update Labels
- Personalized Medicine Providers, FDA Has Your Back
- GNC Shakes False Label Class Action Over Meal Bars
- Thermo Fisher Makes Commitments To EU In Life Tech Buy
- J&J To Pay $400M Over Criminal Charge In Risperdal Case
- FTC Patent License Rule Sure To Annoy Drugmakers
- Wyeth, Elan Investors Slam $1.2B SAC Plea Bargain
- Fen-Phen Plaintiffs Cut From Napoli Bern Settlement Suit
- Iclusig Deaths Won't Stall FDA's Speedier Drug Approvals
- Covington Guides Salix's $2.6B Gastro Drugmaker Buy
- Amarin Accused Of Pumping Up Stocks Before FDA Snub
- Carving A Path Around 9th Circ.'s Gerber Decision
- Travelers Receives Sharp Rebuke In Heparin Discovery Fight
- Calif. Supplement Maker Hawked Absent Ingredient, Suit Says
- FDA Needs Rule Change For DMAA Crackdown, Suit Says
- USPTO's Power To Nix Verdicts Ripe For Supreme Court
- FTC Redefines Which Drug Patent Deals Need Antitrust OK
- McKesson Inks $14M Deal In Wis. Drug Price-Rigging Suit
- EPA Sues Dow, Exxon, Others For NJ Superfund Site Cleanup
- Drugmakers Take Reglan Preemption Appeal To Pa. High Court
- Fed. Circ. Axes E8 Pharmaceuticals' Gene Testing IP Claims
- Sandoz Appeals Eye Drug Patent Verdict To Fed. Circ.
- Elliott Unveils 10% Stake In $8.2B Takeover Target Celesio
- Ex-NFL Doc Ends $2M Indemnity Suit Against Smith & Nephew
- Why High Stakes Legal Failures Happen
- 'Rough Justice' Is Not Justice
- Insurers Settle Alaven's $10M Reglan Injury Coverage Suit
- Ballard Spahr Lands IP, Antitrust Aces For Atlanta, DC
- Fed. Circ. Won't Review Disposal Of Baxter's $23.5M IP Award
- Bristol-Myers Wins Patent Fight Over Generic HIV Drug
- Justices Wary Of Putting Burden Of Proof On IP Licensees
- Teva Asks Supreme Court For Stay On MS Drug Patent Ruling
- Allergan Triumphs In 'Botox' Trademark Dispute
- Iowa Telemedicine Abortion Ban Delayed By Judge
- Deals Rumor Mill: NYSE Euronext, One Equity Partners, KKR
- Pfizer Beat Sanofi To Isolated DNA Patent, Fed. Circ. Says
- Citing $2B J&J Deal, Pa. Pol Floats State False Claims Act
- Bard Denied Atty Fees For Dropped Vaginal Mesh Bellwether
- State Claims Reinstated In Novartis Elidel FCA Suit
- Epstein Becker Green Brings On FDA Pro From Hodgson Russ
- Skadden Steers Endo's $1.6B Paladin Labs Buy
- Illumina Can't Escape $115M Judgment In Syntrix Patent Suit
- Chief Justice Roberts Turns Up The Heat On Cy Pres Pacts
- With $2B J&J Deal, FCA Proves It's Still The Anti-Fraud King
- Justices May Raise Bar For Licensees Challenging Patents
- J&J's $2.2B Deal A Last Hurrah For Off-Label Crackdown
- Tomato Extract Maker Drops IP Suit Against Competitor
- Fed. Circ. Nixes Injunction On J&J Rival's Glucose Strips
- Roche Inks $549M Deal To License 'Superbug' Antibiotic
- Justices Won't Touch Facebook's $9.5M 'Beacon' Privacy Deal
- Takeda Triumphs In Suits To Block Generic Dexilant
- High Court Won't Hear Okla. Appeal Over Abortion-Drug Law
- Finding The Sweet Spot In Evaporated Cane Juice Cases
- Supreme Court Trends In Federal Preemption
- J&J Inks $2.2B Settlement For Off-Label Marketing, Kickbacks
- Otsuka Says Wockhardt's ANDA Infringes Abilify Patent
- 3 Pitfalls Posed By Over-The-Counter Drug Recalls
- Syringe Maker Faces Securities Suit Amid Whistleblower Row
- Elan Investors Say SAC Should Admit Insider Trading In Plea
- Supreme Court Asked To Take Up Lupron Labeling Suit
- Elan Win In IP Feud Over Skelaxin Confirmed By Judge
- OrbiMed Forms $735M VC Fund To Invest In Health Industry
- Warner Chilcott Sues Mylan To Block Generic Lo Loestrin
- New Prop 65 Is A Relief For Calif. Manufacturers
- Fed. Circ. Ruling Provides Guidance On 'Reason To Combine'
- Ariad Opts For Poison Pill After Hedge Fund Buy-In